Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | REN | P00797 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PEPD | P12955 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | CMA1 | P23946 | 2/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10297415 | 1.00 | ACE (0.49) | ACEKMT2ARENKDM4EF2 | |
| SCHEMBL10297420 | 1.00 | ACE (0.49) | ACEKMT2ARENKDM4EF2 | |
| SCHEMBL8054270 | 1.00 | ACE (0.49) | ACEKMT2ARENKDM4EF2 | |
| SCHEMBL17348387 | 0.95 | ACE (0.53) | ACEKMT2ARENKDM4EF2 | |
| SCHEMBL6242739 | 0.95 | ACE (0.53) | ACEKMT2ARENKDM4EF2 | |
| SCHEMBL13950858 | 0.95 | ACE (0.53) | ACEKMT2ARENKDM4EF2 | |
| SCHEMBL2262901 | 0.95 | ACE (0.53) | ACEKMT2ARENKDM4EF2 | |
| SCHEMBL16000759 | 0.95 | ACE (0.53) | ACEKMT2ARENKDM4EF2 | |
| SCHEMBL10653958 | 0.90 | ACE (0.49) | ACEKMT2ARENKDM4EF2 | |
| SCHEMBL29787416 | 0.90 | CMA1 (0.53) | ACERENKDM4EF2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226155-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2017-08-10 | — | — | US | disclosed |
| US-9629921-B2 | Smart pro-drugs of serine protease inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2017-04-25 | — | — | US | disclosed |
| US-20130303435-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | BACH BIOSCIENCES, LLC | 2013-11-14 | — | — | US | disclosed |
| EP-2319523-A1 | Serine protease inhibitors | Trustees Of Tufts College (US) | 2011-05-11 | — | — | EP | disclosed |
| EP-2204181-A2 | Protease inhibitors | Trustees of Tufts College (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20100168032-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100168032-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2010-07-01 | — | — | US | disclosed |
| US-7691967-B2 | Smart pro-drugs of serine protease inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2010-04-06 | — | — | US | disclosed |
| EP-0693080-B1 | NEW GLUCOCORTICOIDS | SCHERING AG (DE) | 1998-04-22 | — | — | EP | disclosed |
| US-5616573-A | Glucocorticoids | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-04-01 | — | — | US | disclosed |
| EP-0693080-A1 | NEW GLUCOCORTICOIDS | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-01-24 | — | — | EP | disclosed |
| WO-1994022898-A1 | NEW GLUCOCORTICOIDS | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-10-13 | — | — | WO | disclosed |
| US-4029772-A | FOR TREATMENT OF PANCREATITIS | MERCK & CO., INC. (US) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303435-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | FAP, PREP, CTSC | ACE 49/4885KMT2A 4250/4885REN 482/4885 |
| US-20170226155-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | FAP, PREP, CTSC | ACE 49/4885KMT2A 4250/4885REN 482/4885 |
| US-20100168032-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | FAP, PREP, CTSC | ACE 49/4885KMT2A 4250/4885REN 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.